Do you use PAM50 LumB status to guide not just ADT use but also the decision to include elective pelvic nodal irradiation in patients receiving salvage RT after prostatectomy?

I think evidence for PAM50 as a predictive biomarker is becoming increasingly compelling, but I am not yet using it to determine either ADT use or to include (or withhold) pelvic nodal radiation in the salvage RT setting.

At ASTRO 2025, NRG-GU006 provided prospective randomized evidence for PAM50 as...

At ASTRO 2026, a post-hoc analysis of NRG/RTOG-0534 was presented evaluating the association between PAM50 subtype and treatment outcomes. This analysis is complementary to NRG-GU006, which was the first prospective, biomarker-stratified randomized trial to demonstrate that patients with luminal B t...

In NRG/RTOG-0534, when comparing FFP between Arm 3 (PBRT + STADT + PLNRT) vs. Arm 2 (PBRT + STADT), the PLNRT HR was 0.9 (P=0.63) in the non-LumB patients and 0.9 (P=0.69) in the LumB patients. There was a more pronounced difference for MFS, where the HR was 1.12 (P=0.7) in the non-LumB patients vs....